Federated Hermes
RAPP

Federated Hermes’s Rapport Therapeutics RAPP Stock Holding History

Federated Hermes’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
240
+97
+68% +$3.56K ﹤0.01% 1853
2026
Q1 		$4.47K Buy
143
+88
+160% +$2.48K ﹤0.01% 1902
2025
Q4 		$1.67K Buy
+55
New +$1.52K ﹤0.01% 1981

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Federated Hermes's RAPP Position: Q2 2026 in Review

Federated Hermes increased its Rapport Therapeutics (RAPP) stake by 68% in Q2 2026, buying an estimated $3.56K and bringing the position to 240 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1853.

Federated Hermes first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Federated Hermes held 240 shares of Rapport Therapeutics worth $10K as of Q2 2026.
  • Federated Hermes bought 97 Rapport Therapeutics shares in Q2 2026, an estimated $3.56K.
  • Rapport Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1853 holding.
  • Federated Hermes first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.